tbuckley/cabot-search huggingface dataset:
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction
Authors: Søren L. Kristensen, Ulrik M. Mogensen, Pardeep S. Jhund, Mark C. Petrie, David Preiss, Sithu Win, Lars Køber, Robert S. McKelvie, Michael R. Zile, Inder S. Anand, Michel Komajda, John S. Gottdiener, Peter E. Carson, John J. V. McMurray
Journal: Circulation (2017)

Background: In patients with heart failure and preserved ejection fraction, little is known about the characteristics of, and outcomes in, those with and without diabetes mellitus. Methods: We examined clinical and echocardiographic characteristics and outcomes in the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) according to history of diabetes mellitus. Cox regression models were used to estimate hazard ratios for cardiovascular outcomes adjusted for known predictors, including age, sex, natriuretic peptides, and comorbidity. Echocardiographic data were available in 745 patients and were additionally adjusted for in supplementary analyses. Results: Overall, 1134 of 4128 patients (27%) had diabetes mellitus. Compared with those without diabetes mellitus, they were more likely to have a history of myocardial infarction (28% versus 22%), higher body mass index (31 versus 29 kg/m 2 ), worse Minnesota Living With Heart Failure score (48 versus 40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 versus 320 pg/mL; all P &lt;0.01), more signs of congestion, but no significant difference in left ventricular ejection fraction. Patients with diabetes mellitus had a greater left ventricular mass and left atrial area than patients without diabetes mellitus. Doppler E-wave velocity (86 versus 76 cm/s; P &lt;0.0001) and the E/e’ ratio (11.7 versus 10.4; P =0.010) were higher in patients with diabetes mellitus. Over a median follow-up of 4.1 years, cardiovascular death or heart failure hospitalization occurred in 34% of patients with diabetes mellitus versus 22% of those without diabetes mellitus (adjusted hazard ratio, 1.75; 95% confidence interval, 1.49–2.05), and 28% versus 19% of patients with and without diabetes mellitus died (adjusted hazard ratio, 1.59; confidence interval, 1.33–1.91). Conclusions: In heart failure with preserved ejection fraction, patients with diabetes mellitus have more signs of congestion, worse quality of life, higher N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosis. They also display greater structural and functional echocardiographic abnormalities. Further investigation is needed to determine the mediators of the adverse impact of diabetes mellitus on outcomes in heart failure with preserved ejection fraction and whether they are modifiable. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00095238.
Mucosectomie endoscopique pour dysplasie de haut grade ou adénocarcinome sur endobrachyoesophage chez 35 malades: résultats à 5 ans
Authors: T Barrioz, F Kaffy, E Blanchet, P Babin, C Silvain, JM Gougeon, M Beauchant
Journal: Endoscopy (2005)

L'incidence de l'adénocarcinome de l'oesophage a nettement augmenté ces 3 dernières décénnies. La détection et la résection précoces des dysplasies de haut grade (DHG) et cancers superficiels (CS) sur EBO devraient améliorer la survie des malades. Dans cette indication, la mucosectomie endoscopique semble une bonne alternative à la chirurgie dont la morbi-mortalité reste élevée chez ces malades souvent agés.
A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.
Authors: Nina Bhardwaj, Anna C. Pavlick, Marc S. Ernstoff, Brent Allen Hanks, Mark R. Albertini, Jason John Luke, Michael Jay Yellin, Tibor Keler, Thomas A. Davis, Andrea Crocker, Laura Vitale, Chihiro Morishima, Philip Adam Friedlander, Martin A. Cheever, Steven Fling
Journal: Journal of Clinical Oncology (2016)

9589 Background: Patients (pts) with high-risk melanoma have a 20-60% recurrence rate with 5-year OS between 45% and 70%. The adjuvant setting is an opportunity to test prevention vaccines that may have efficacy against disease recurrence. We evaluated CDX301, a recombinant human Flt3 ligand (Flt3L), plus vaccination with CDX1401, a fusion protein consisting of human monoclonal IgG1 antibody targeting the dendritic cell (DC) receptor DEC-205 linked to the NY-ESO-1 tumor antigen, in a phase II, open-label, multicenter, randomized study of subjects with resected melanoma, to determine whether immune responses to NY-ESO-1 elicited by vaccination with CDX1401 + poly-ICLC are substantially increased by prior expansion of circulating DC with Flt3L therapy. Methods: 60 pts with resected melanoma were randomized to two cohorts: Cohort 1 received CDX301 pretreatment (25 ug/kg SC x 10 days) in 2 of 4 monthly cycles of vaccination with CDX1401 (1mg IC) + poly-ICLC (2mg SC, days 1 and 2). Cohort 2 received 4 monthly cycles of vaccine with CDX1401 and poly-ICLC without prior CDX301. We also assessed immunogenicity to other melanoma-associated antigens and memory viral responses, character of PBMC subsets, and safety, tolerability and clinical efficacy of the regimens. Results: Both treatments were well tolerated with grade 1-2 AEs of chills, injection site erythema and pain, fever and myalgias most common. Disease recurred in 8 of 60 pts. Two of the 8 pts progressed prior to completing 4 cycles of treatment. Preliminary analyses show substantial (between ~15- to ~200-fold) increases of PBMC innate immune cells (DC, monocytes and NK cells) in subjects from cohort 1 vs cohort 2. Further, there was development of higher anti-NY-ESO-1 antibody titers in cohort 1 vs cohort 2. Comparative immune cell gene expression profiling of PBMC are consistent with these differences. Finally, significant NY-ESO-1 specific immune T cell responses were observed and differences between cohorts are being analyzed. Data from all 60 patients will be presented. Conclusions: DC mobilization with Flt3L is safe and may enhance responses to DC targeted vaccines. Clinical trial information: NCT02129075.
Is ERCP beneficial in patients with malignant biliary strictures plus liver metastases?
Authors: P McConville, A Murdock, C Larkin, TCK Tham
Journal: Endoscopy (2005)

Background: It is not known if patients with liver metastases and concomitant biliary strictures will benefit from ERCP. The aim of this study was to see if ERCP plus stenting produced a reduction in bilirubin and symptomatic improvement.
The Unnatural History of the Ventricular Septal Defect
Authors: Myrthe E. Menting, Judith A.A.E. Cuypers, Petra Opić, Elisabeth M.W.J. Utens, Maarten Witsenburg, Annemien E. van den Bosch, Ron T. van Domburg, Folkert J. Meijboom, Eric Boersma, Ad J.J.C. Bogers, Jolien W. Roos-Hesselink
Journal: Journal of the American College of Cardiology (2015)
Mediators of the Association Between Mortality Risk and Socioeconomic Status—Reply
Authors: Mehdi H. Shishehbor, David Litaker, Michael S. Lauer
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Website of the week: Death and dying
Authors: Douglas Carnall
Journal: BMJ (2000)

Death is the new sex, last great taboo in Western society and Western medicine, as Richard Smith discusses in his editorial (p 129). In the trinity of births, marriages, and deaths, only death does not have glossy magazines devoted to stylish consumption at the attendant ceremonies. On the web, of course, you can find anything about anything, and the Natural Death Centre (www.naturaldeath.org.uk/) is the social invention of a whole community who have thought seriously about the issues and plan to practice what they preach. The website is a compelling mix of rhetoric and practical guidance. There is non-quantitative information on the effects of cremation on atmospheric pollution, and a list of more than 100 sites around the United Kingdom where you can be buried and a tree planted over your head (www.globalideasbank.org/greenburial.html). Nicholas Albery, the centre's founder and editor of The Natural Death Handbook (www.globalideasbank.org/natdeath/ndhbook.html), plans, after his death, to be lowered on ropes beneath the turf of a nature reserve, wrapped only in a cotton shroud (the body is stiffened with a single plank in case you wondered).

Back in the mainstream (if I can use that term about anything on the web), About.com's coalescence of information on death and dying at http://dying.about.com/health/dying/mbody.htm is probably most useful. Because writing little countdown routines is a good beginner's exercise in computer programming, death clocks abound on the internet. Try www.deathclock.com/, which counts down the seconds to your death in a new browser window for you—an excellent spur to more effective time management.
Predicting adverse cardiac events after myocardial infarction and thrombolysis
Authors: A. Archbold, A. D Timmis, S. Grant, R. Steeds, K. Channer, S. Basu, R Senior, A Lahiri, C Dore
Journal: BMJ (1997)

Data are not now collected by ethnic group in South AfricaEditor-Claire Hilton notes that since April 1995 British hospitals have had to collect data on each patient's ethnic group. 1 In the United States this is standard practice.In the Morbidity and Mortality Weekly Report data on numerous variables relating to the health and ill health of black and white people are regularly given 2 -as also, on occasion, are data on Hispanics, American Indians, Inuits, and Pacific Islanders.In South Africa precisely the converse has occurred.Ethnic subdivisions have stopped appearing in reports from the Central Statistics Services, and thus mortalities are no longer given for the constituent populations (black, Asian, coloured (Eur-African-Malay), and white), only for the combined population.Additionally, in our big cities annual reports from public health departments provide only combined data on morbidity and mortality.Disadvantages are many.Recently, colleagues and I reviewed changes in the total death rate and the death rate from coronary heart disease in South African populations. 3 We found that, from 1978 to 1989, mortality from coronary heart disease fell by 56% in the white population and by 36% in each of the Indian and coloured populations.Because changes in mortality from this foremost "killer" are continuing we intended to update our information.But this is now precluded.Currently, desegregation does not apply to our national cancer registry.But if it did how, for example, could benefits from Papanicolaou smear tests be assessed?The incidences of cervical cancer in the black and coloured populations are among the highest in the world.The constituent populations of South Africa have a wider divergence in the occurrence of a variety of diseases than occurs in any other country: coronary heart disease, appendicitis, colon cancer, and hip fractures.Interethnic differences in the occurrence of disease, reactivity, and metabolism are well known elsewhere. 4 In South Africa the change to using combined data will make it harder to identify and quantify the target populations who are in most need of help, as well as severely stultifying research on the occurrence of disease and on combating it.Hilton is right, of course, that the level of treatment is affected by ethnic group.Recently, in the United States the effect of race and income on mortality and the use of services among beneficiaries of Medicare was investigated; both race and income were shown as having substantial prejudicial effects, that of race being much more pronounced than that of income. 5This is a matter of universal shame.
Smoking ban in psychiatric hospital led to drop in violent assaults
Authors: Anne Gulland
Journal: BMJ (2017)

The introduction of a smoking ban in one of the UK’s largest mental health trusts led to a 39% drop in violence, a study has found, despite long held assumptions that banning cigarettes in psychiatric settings would lead to an increase in assaults.1

Researchers looked at the impact of the smoke-free policy on 38 inpatient wards at the South London and Maudsley NHS Foundation Trust. They analysed the number of assaults up to 30 months before the policy was introduced in October 2014 and 12 months afterwards. …
Role of tumor infiltrating lymphocytes (TILs) in HER2+ metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C) (EMILIA Trial).
Authors: Sunil S. Badve, Yesim Gokmen-Polar, Silke Hoersch, Jin Xu, Josef Ruschoff, Sanne de Haas, Sunil Verma
Journal: Journal of Clinical Oncology (2016)

607 Background: In the phase 3 EMILIA trial, administration of T-DM1 significantly prolonged progression-free survival (PFS) and overall survival (OS) with less toxicity than L+C in patients with HER2+ MBC previously treated with trastuzumab and a taxane. In prior studies in early BC, TILs were shown to be prognostic as well as predictive of response to HER2-targeted therapy in HER2+ breast cancer, but inconsistencies exist. We sought to understand whether TILs were associated with outcomes in patients treated with T-DM1 or L+C in EMILIA. Methods: Histology slides from biopsies, collected in the metastatic setting only, were reviewed by 2 observers. The presence and number of TILs was determined in a blinded manner and the association with PFS and OS in each of the study arms was assessed using univariate and multivariate cox proportional hazard regression models including stratification factors as covariates. Results: Ninety-five cases, representing 9.6% of the parent study population (n = 991), were eligible for this substudy. This subset was not representative of the parent study with regard to stratification factors and outcome (PFS + OS). Hence, the analysis of each arm was performed separately. TILs were absent (0) in 46.2% of cases in the L+C arm and 37.2% of the T-DM1 arm. TILs greater than 10% were seen in 13.5% and 32.6% in the L+C and T-DM1 arms, respectively. In the L+C arm, a numerically improved outcome in terms of hazard ratios for PFS and OS was seen in the absence of TILs (0) when compared to those in which TILs were present ( ≥ 1) in both the univariate and multivariate analyses. In the T-DM1 arm, no trend for association between TILs and PFS or OS was observed. No differences were observed with a higher TIL cutoff (TIL > 10) in any treatment arm. Conclusions: Although the current analyses are exploratory and have important limitations, the data suggest that TILs are infrequent in MBC. Additionally, the impact of TILs may vary based on HER2 targeted therapy. Further studies are necessary to investigate the clinical utility of TILs, in freshly obtained biopsies, in HER2+ MBC and their association with outcomes to HER2-targeted therapies.
Relationship between tumor characteristics and HER2/neu overexpression with response and outcome in locally advanced breast cancer (LABC) patients (pts) treated with neoadjuvant anthracycline-based chemotherapy (CHT)
Authors: A. J. Fernandez Sagarra, C. Alvarenga, M. Alvarenga, M. L. Kraft, L. C. Teixeira
Journal: Journal of Clinical Oncology (2006)

10698 Objectives: To retrospectively evaluate the relationship between HER2/neu status, pts’ characteristics, prognostic factors and clinical outcome in LABC women treated with neoadjuvant anthracycline-based CHT. Patients and Methods: 118 pts. with stage IIIA-B LABC, excluding inflammatory cancer, were included. HER2 overexpression was evaluated by immunohistochemistry (IHC), only IHC 3+ were defined as positive. The disease-free survival (DFS) was calculated according to Kaplan-Meier method. Fisher test, hazard ratios with 95% interval confidence, and Cox or Wilcoxon models were used. Kruskall-Wallis was used for comparison between medians. Results: Median age was 49 y (range: 31–69); 66 were pre-menopausal, 43 were stage IIIA and 77 IIIB; 59 pts. were N2. Primary tumor average size was 70 mm; 44 tumors were ER+, 43 PR+, 26 (22%) HER 3+, 104 histological grade III, 57 nuclear grade III. Seventy-four pts. (62.7%) achieved objective responses, with 7 complete clinical remissions. There was 1 progressive disease and only 3 pts. (2.5%) didn’t undertake mastectomy. After surgery, four pts. (3.5%) were evaluated as pathological complete remission, 6 (5.2%) with microscopic residual disease and 105 with macroscopic residual tumor. The median DFS was 19 months for the whole group and 39,6 and 31,6 for those achieving complete pathological remission and microscopic residual disease, respectively. There was no association between HER2/neu overexpression and pts’ characteristics, tumor prognostic factors nor with clinical or pathological responses. Negative PR, high tumor nuclear grade, clinical stage IIIA and complete clinical response were predictive factors for pathological response. In multivariate analysis, only pathological lymph node status was prognostic factor for DFS. Conclusions: There was no significant association between HER2 overexpression, tumor prognostic factors and clinical or pathological response to neoadjuvant CHT. Negative PR, high nuclear tumor grade, clinical stage IIIA and clinical complete response were associated to complete pathological response. Lymph node status was a strong prognostic factor for DFS. No significant financial relationships to disclose.
Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database
Authors: Chang Su, Kevin A. Nguyen, Harrison X. Bai, Ya Cao, Yongguang Tao, Rong Xiao, Giorgos Karakousis, Paul J. Zhang, Guiying Zhang
Journal: Journal of the American Academy of Dermatology (2017)
THE EFFECTS OF FATIGUE ON SCAPULA KINEMATICS DURING THROWING IN ELITE TEAM HANDBALL PLAYERS; DOES PAIN INFLUENCE? A PRELIMINARY STUDY
Authors: Tina Piil Torabi, Birgit Juul-Kristensen, Mogens Dam, Frederik H. Andersen, Lasse Malchow-Møller, Mette K Zebis, Merete Møller, Jesper Bencke
Journal: British Journal of Sports Medicine (2017)

Background Non-traumatic shoulder injuries are common in overhead sports, however many athletes still participate in their sport despite pain. Non-optimal scapula kinematics at the instant of maximal humeral external rotation (HumExtRot) is considered a risk factor in overhead throwing sports. Objective The aim of the study was to investigate whether a functional fatigue protocol affects scapula kinematics during throwing, and whether this effect is different between players who are pain-free and participating with pain. Design A controlled intervention study. Setting 3D Motion Analysis Laboratory with 8 cameras (Vicon T40, Oxford, UK). Patients (or Participants) 16 adult, mean age 21,9(2,4) years, elite female team handball players were recruited from top 2 leagues in Denmark. The participants were divided into two groups; 8 subjects playing with pain(P) and 8 subjects playing without pain(NP) served as controls. Interventions (or Assessment of Risk Factors) Measurements of scapula and gleno-humeral kinematics were collected during maximal throws before and after a fatiguing protocol, containing 60 alternated submaximal-and maximal throws. Main Outcome Measurements Maximal HumExtRot in relation to scapula, scapula posterior tilt (ScapPostTilt), scapula retraction (ScapRetr) and scapula upward rotation (ScapUpRot) at the instant of maximal HumExtRot were selected as outcome parameters. Overall effects for the whole group, between groups and differences in fatigue development between groups were evaluated using 2-way repeated measures ANOVA. Results As a result of fatigue, the group (n=16) showed less ScapPostTilt (Mean=5,5°, SD=6,3°, p=0.004), ScapUpRot (Mean=3,7°, SD=4°,p=0,003), and less ScapRetr (Mean=2,7°, SD=4°, p=0,044), and the HumExtRot increased (Mean=3,3°, SD=5,9°, p=0,048). No significant differences between groups were found, however a tendency towards greater HumExtRot was observed (Mean difference=15.2°, SD=16.9°, p=0,089), for players with NP. Conclusions The results indicate that fatigue has a detrimental effect on scapula and gleno-humeral kinematics, which may increase the risk of non-traumatic shoulder injuries. However P-players did not respond differently to fatigue-development.
Tumor-selective lipopolyplex encapsulated small active RNA hampers colorectal cancer growth in vitro and in orthotopic murine
Authors: Lu-Lu Wang, Chen-Lin Feng, Wen-Sheng Zheng, Shuai Huang, Wen-Xuan Zhang, Hong-Na Wu, Yun Zhan, Yan-Xing Han, Song Wu, Jian-Dong Jiang
Journal: Biomaterials (2017)
Abstract 2795: Traditional Risk Factors & Coronary Plaque Composition Assessed by Non Invasive CT Angiography in Asymptomatic Individuals
Authors: Juan J Rivera, Khurram Nasir, Roger S Blumenthal, Yeonyee E Yoon, Song A Chang, Eue-Keun Choi, Sang-il Choi, Eun-Ju Chun, Dong-Joo Choi, Hyuk-Jae Chang
Journal: Circulation (2008)

Objective: Although prior studies have shown that traditional cardiovascular (CV) risk factors are associated with the burden of coronary atherosclerosis, less is known about the relationship of ri...